We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
In the latest trading session, DaVita HealthCare (DVA - Free Report) closed at $151.99, marking a +1.28% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.04%. Meanwhile, the Dow lost 0.57%, and the Nasdaq, a tech-heavy index, added 0.04%.
The stock of kidney dialysis provider has fallen by 2.36% in the past month, lagging the Medical sector's loss of 0.72% and the S&P 500's gain of 12.24%.
The upcoming earnings release of DaVita HealthCare will be of great interest to investors. The company's earnings report is expected on May 5, 2026. In that report, analysts expect DaVita HealthCare to post earnings of $2.41 per share. This would mark year-over-year growth of 20.5%. Meanwhile, the latest consensus estimate predicts the revenue to be $3.3 billion, indicating a 2.36% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $14.16 per share and revenue of $14.11 billion. These totals would mark changes of +31.35% and +3.41%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare is currently sporting a Zacks Rank of #3 (Hold).
From a valuation perspective, DaVita HealthCare is currently exchanging hands at a Forward P/E ratio of 10.6. This represents a discount compared to its industry average Forward P/E of 17.9.
It's also important to note that DVA currently trades at a PEG ratio of 0.52. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Outpatient and Home Healthcare was holding an average PEG ratio of 1.79 at yesterday's closing price.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 151, positioning it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note
In the latest trading session, DaVita HealthCare (DVA - Free Report) closed at $151.99, marking a +1.28% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.04%. Meanwhile, the Dow lost 0.57%, and the Nasdaq, a tech-heavy index, added 0.04%.
The stock of kidney dialysis provider has fallen by 2.36% in the past month, lagging the Medical sector's loss of 0.72% and the S&P 500's gain of 12.24%.
The upcoming earnings release of DaVita HealthCare will be of great interest to investors. The company's earnings report is expected on May 5, 2026. In that report, analysts expect DaVita HealthCare to post earnings of $2.41 per share. This would mark year-over-year growth of 20.5%. Meanwhile, the latest consensus estimate predicts the revenue to be $3.3 billion, indicating a 2.36% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $14.16 per share and revenue of $14.11 billion. These totals would mark changes of +31.35% and +3.41%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare is currently sporting a Zacks Rank of #3 (Hold).
From a valuation perspective, DaVita HealthCare is currently exchanging hands at a Forward P/E ratio of 10.6. This represents a discount compared to its industry average Forward P/E of 17.9.
It's also important to note that DVA currently trades at a PEG ratio of 0.52. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Outpatient and Home Healthcare was holding an average PEG ratio of 1.79 at yesterday's closing price.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 151, positioning it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.